November 03, 2022

"Uncover What Real-World Data Means for Moderate-To-Severe Psoriasis Patients” – A Sun Pharma sponsored episode

This episode is intended for patients with moderate-to-severe plaque psoriasis and health care providers who treat this condition.

Treatment options backed by real-world evidence mean more opportunities for those living with moderate-to-severe plaque psoriasis. Join Steve Rozzo, Ph.D., Associate Vice President and Head, Biologics Medical Affairs, Sun Pharma, North America, and Neal Bhatia, M.D., Therapeutics Clinical Research in San Diego, CA, in a Q&A discussion on real-world clinical data of ILUMYA® and what the findings mean for moderate-to-severe plaque psoriasis patients and health care providers.

This episode is sponsored by Sun Pharma.

Find Important Safety Information.

Related Items

Stay in the Know

Expert tips, can’t-miss events, and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity NavigatorCommunity Health Charities logo

Copyright © 1996-2024 National Psoriasis Foundation/USA

Duplication, rebroadcast, republication, or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).

NPF does not endorse or accept any responsibility for the content of external websites.

NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.